Patents Examined by Rachael E Bredefeld
  • Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof
    Patent number: 10485893
    Abstract: This disclosure provides for an antimicrobial pressure sensitive adhesive composition that includes a sequestered peroxide source and devices that incorporate such a composition.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 26, 2019
    Assignee: Sarasota Medical Products, Inc.
    Inventor: Walter F. Leise, III
  • Pharmaceutical compositions for inhibiting angiogenesis comprising plant-derived natural compound
    Patent number: 10478440
    Abstract: The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: November 19, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ho Jeong Kwon, Yong Hyo Kim
  • Skin engaging shaving aid member comprising at least one thermally resilient sensate
    Patent number: 10478388
    Abstract: A skin engaging shaving aid member suitable for use in a shaving device, said skin engaging shaving aid member comprising a thermally resilient sensate such as N-substituted menthanecarboxamide.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 19, 2019
    Assignee: The Gillette Company LLC
    Inventors: Xiandong Wang, Fatima Abdulhussain Jabalpurwala, Katharine Anne Bakes
  • Decoy peptides inhibiting protein phosphatase 1-medicated dephosphorylation of phospholamban
    Patent number: 10479816
    Abstract: The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X1-Ala-X2-X3-Ile-Glu-X4 (I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 19, 2019
    Assignee: BETHPHAGEN INC.
    Inventors: Woo Jin Park, Roger J. Hajjar, Jae Gyun Oh
  • Methods and compositions using ADAM10 inhibitors to treat bacterial infections
    Patent number: 10472391
    Abstract: Certain embodiments are directed to compositions and methods of inhibiting a pathogenic bacterial infection involving ADAM10, specifically a method for treating pore-forming toxin-inducted pathology caused by exposure to staphylococcus in a subject, comprising administering an effective amount of a ADAM10 inhibitor to a patient. The methods include treating pneumonia or inhibiting disruption to epithelial barrier in a subject, having or at risk of developing staphylococcal infection.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: November 12, 2019
    Assignees: THE UNIVERSITY OF CHICAGO, SRI INTERNATIONAL
    Inventors: Juliane Bubeck Wardenburg, Katherine Weh, Leyi Gong
  • Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
    Patent number: 10471017
    Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more task-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 12, 2019
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventors: Jin-Wang Lai, Gopi M. Venkatesh, Ken Kangyi Qian
  • Use of Cyt1Aa as broad spectrum targeting domain for insecticidal proteins with basic research and biotechnology applications
    Patent number: 10472397
    Abstract: A chimeric protein comprising a cytolytic ?-endotoxin portion and a heterologous polypeptide portion is provided. Nucleic acids encoding the chimeric protein are also provided. In some cases, the chimeric protein can be expressed in parasporal inclusions of Bacillus thuringiensis. In certain cases, the cytolytic ?-endotoxin portion can include Cyt1Aa, and the heterologous portion can include an insecticidal polypeptide. The chimeric protein can be expressed in a suitable B. thuringiensi cell and purified as parasporal inclusions. Also provided is a method of controlling insects by exposing an insect to a chimerical insecticidal protein.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Brian A. Federici, Dennis Bideshi, Hyun-Woo Park, Robert Hice, Tianyun Su
  • Non-hormonal steroid modulators of NF-?? for treatment of disease
    Patent number: 10464967
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: November 5, 2019
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Nagaraju (Raju) Kanneboyina, Jesse Damsker
  • Therapeutic formulation for reduced drug side effects
    Patent number: 10463633
    Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: November 5, 2019
    Assignee: KemPharm, Inc.
    Inventor: Subhash Desai
  • Nutritive polypeptides and formulations thereof, and methods of production and use thereof
    Patent number: 10463711
    Abstract: Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Axcella Health Inc.
    Inventors: Michael Hamill, Brett Boghigian, Caitlyn Harvey, David Berry, David Young, Geoffrey Von Maltzahn, John Kramarczyk, Jameson Rogers, Kathryn Heard, Michael Doherty, Nathaniel Silver, Phillip Samayoa, Subhayu Basu, Shaila Rahman, Vimal Vaidya, Ying-Ja Chen
  • Therapeutic approaches for treating CMT and related disorders
    Patent number: 10463640
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 5, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Oil-in-water emulsion
    Patent number: 10449126
    Abstract: The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and in that it contains at least one lipophilic surface-active agent with an HLB ranging from 2 to 5, at least one hydrophilic surface-active agent with an HLB ranging from 8 to 12 and at least one amphiphilic compound of ionic nature at a pH ranging from 3 to 5.5.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: October 22, 2019
    Assignee: L'OREAL
    Inventors: Florence L'Alloret, Jean-Thierry Simonnet
  • Mixtures of sabadilla alkaloids and phenylpyrazoles and uses thereof
    Patent number: 10448641
    Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and at least one phenylpyrazole and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and at least one phenylpyrazole.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 22, 2019
    Assignee: MCLAUGHLIN GORMLEY KING COMPANY
    Inventors: Robert A. Suranyi, Donald L. Sundquist
  • Therapeutic approaches for treating CMT and related disorders
    Patent number: 10441558
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: October 15, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Method for inhibiting HIV replication in mammal and human cells
    Patent number: 10434137
    Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 8, 2019
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
  • Compositions for the treatment of Fragile X syndrome
    Patent number: 10435366
    Abstract: The present invention relates to a composition comprising a maxi-K potassium channel opener the use in the treatment of fragile X syndrome. More specifically the present invention relates to a composition comprising a fluoro-oxindole or a chloro-oxindole for use in the treatment of fragile X syndrome.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: October 8, 2019
    Assignees: Centre National de la Recherche Scientifique, Centre Hospitalier Regional d'Orleans, University d'Orleans
    Inventors: Sylvain Briault, Olivier Perche
  • Cystine knot scaffold platform
    Patent number: 10428125
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: October 1, 2019
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
  • Use of maleimide derivatives for preventing and treating cancer
    Patent number: 10420754
    Abstract: The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: September 24, 2019
    Assignee: Centogene AG
    Inventors: Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Anahit Pews-Davtyan
  • Peptide compounds to regulate the complement system
    Patent number: 10414799
    Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: September 17, 2019
    Assignee: ReAlta Holdings, LLC
    Inventors: Neel K. Krishna, Kenji Cunnion
  • Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
    Patent number: 10407483
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow